← All trials
NCT04034641
Phase 4Interventional
Studies of FDA-approved drugs to delineate additional information including the drug's risks, benefits, and optimal use.
View on ClinicalTrials.gov ↗Timeline
- Start date
- Nov 1, 2019
- Primary completion
- Dec 31, 2020
- Completion date
- Dec 31, 2021
- First posted
- —
- Last posted
- —
- Enrollment
- 238
- Arms / groups
- 2 / —
- Source
- AACT · ingestion pipeline
Sponsors
- Hangzhou Grand Biologic Pharmaceutical, Inc.Lead sponsor
- Nanchang UniversityCollaborator
- Nanchang UniversityOverall official - principal investigator
- Nanjing Medical UniversityCollaborator
- Wuhan UniversityCollaborator
- Zhejiang Chinese Medical UniversityCollaborator
- Jiao Tong UniversityCollaborator
- Zhejiang UniversityCollaborator
- Zhengzhou UniversityCollaborator
- People's Liberation Army of ChinaCollaborator
Drugs studied
Indications studied
CDEK-curated fields only — the ClinicalTrials.gov results mirror (baseline measures, adverse events, participant flow) is a separate, currently-dormant pipeline; see MIGRATION_PLAN.md.